Medical Xpress November 15, 2024
Stephanie Dutchen, Harvard Medical School

Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people with Usher syndrome type 1F, a rare condition that causes deafness and progressive blindness.

A new way of delivering a corrected version of the faulty gene that causes Usher syndrome—PCDH15—restored hearing in mouse models and showed potential in retinal organoids and for improving , the team reports in the Journal of Clinical Investigation.

This is the second experimental for Usher syndrome developed by the lab of David Corey, the Bertarelli Professor of Translational Medical Science in the Blavatnik Institute at HMS. Earlier research showed that a different gene-delivery strategy restored hearing in mice. The new method provides...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
How Agencies Should Decide Which Costly Drugs To Target With Government March-In Rights
Biotech startups are built on venture capital. Track funding rounds here.
Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin
What might a Trump administration mean for the Biosecure Act?
Flagship, Pfizer alliance yields two more startup deals

Share This Article